Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT01288508 · ClinicalTrials.gov registry record · NA

Investigation of Supra Fiber in the Treatment of Adults With Constipation

A NA study, sponsored by Augusta University.

Completed
Registry status
NA
Development phase
89
Enrollment target

NCT01288508: Completed NA study, sponsored by Augusta University.

NCT01288508 is a NA study that has completed, run by Augusta University. The registered enrollment target is 89 participants, below the 1,404-participant average among 58,714 other NA trials with a reported enrollment target (94% lower). According to ClinicalTrials.gov, the official US trial registry.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT01288508, a NA study, has completed, sponsored by Augusta University.

COMPLETED
Registry status
NA
Development phase
89 participants
Enrollment target

Study Summary

Background: Whether Supra-Fiber, a plum-derived fiber supplement is useful in the treatment of constipation is not known. Supra Fiber is the first fiber supplement that has a blend of whole food fruit as its main ingredient. It contains prunes, pomegranates, blueberries, and Acai berries. Unlike psyllium, which is mostly (90%) insoluble fiber, Supra Fiber is a balanced (50%) blend of insoluble and soluble fiber. This may provide the beneficial effects of fiber, and eliminate potential adverse symptoms of fiber such as bloating, distention, hard bulky stools and excess gas. In this study, we expect to not only evaluate the efficacy but also the palatability and tolerability of Supra Fiber in the treatment of chronic constipation. Aims: 1. To investigate and compare the effects of Supra Fiber (5 grams BID) or psyllium (5 grams BID) on the number of complete spontaneous bowel movements per week, and bowel symptoms. 2. To examine the effects of fiber supplements on taste and quality of life in adults with functional chronic constipation in a randomized, double-blind, parallel group controlled trial. Methods: We propose to enroll 90 subjects with functional constipation in a single blinded, randomized, cross-over study comparing 4 weeks of Supra Fiber with 4 weeks of treatment with Psyllium Data analysis: The primary outcome measure will be the global relief of constipation symptoms as rated by the subject at the end of each phase of the study. Additionally, we will assess several secondary outcome measures that will include the number of Complete Spontaneous Bowel Movements (CSBM) per week, Quality of Life , psychological profile, patient rating of taste on a VAS scale, patient rating of bloating, distension, satiety and fullness and patient rating of constipation-related symptoms. Expected results: We anticipate that treatment with Supra Fiber will improve symptoms of constipation compared to the baseline. This improvement will be comparable or superior to that ac

Primary Outcome

1\. Number of Complete Spontaneous Bowel Movements (CSBM) per week. This will be analyzed from the daily stool diaries (Appendix 1). The CSBM provides a more robust and better assessment of the overall change in bowel function that takes into account not only the stool frequency but also the completeness and satisfaction with bowel function. A CSBM is defined as a bowel movement that is produced without the use of additional laxatives, suppositories or enemas in the previous 24 hours, other than

Interventions

  • DIETARY_SUPPLEMENT Psyllium
  • DIETARY_SUPPLEMENT Supra Fiber

Trial Details

FieldValue
Enrollment Target 89 participants
Start Date 2010-10
Est. Completion 2014-09
Phase NA
Augusta University

106 total trials

What the finished NCT01288508 record still lists

NCT01288508 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 89 participants, a relatively small participant target, below the 1,404-participant average among 58,714 other NA trials with a reported enrollment target (94% lower).

The record links to 0 conditions, and to 2 interventions - of which Psyllium is the first listed.

NCT01288508 does not publish any study locations in the registry export this page uses.

Frequently Asked Questions

What is clinical trial NCT01288508 about?

NCT01288508 is a clinical study titled "Investigation of Supra Fiber in the Treatment of Adults With Constipation". Background: Whether Supra-Fiber, a plum-derived fiber supplement is useful in the treatment of constipation is not known. Supra Fiber is the first fiber supplement that has a blend of whole food fruit as its main ingredient. It contains prunes, pomegranates, blueberries, and Acai berries. Unlike psy...

What is the current status of trial NCT01288508?

This trial is currently completed. It is a NA study. The enrollment target is 89 participants. The study started on 2010-10. Estimated completion is 2014-09.

What interventions are being tested in trial NCT01288508?

The interventions under investigation include: Psyllium (DIETARY_SUPPLEMENT), Supra Fiber (DIETARY_SUPPLEMENT).

Who is sponsoring clinical trial NCT01288508?

This trial is sponsored by Augusta University, which has 106 total clinical trials registered on ClinicalTrials.gov.

How this trial's enrollment target compares

Where NCT01288508's enrollment target sits among peer trials

89 972nd of 2000 higher than 1,029 of 2,000 other NA trials

participants (enrollment target), bucketed by value

Each bar is a band; taller bars hold more other NA trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.

Source ClinicalTrials.gov registry export · 2026-08-08

Nationwide trials with similar profiles

Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.

Similar enrollment target

  • NCT03682289 · 89 participants · Phase 2

    Ceralasertib (AZD6738) Alone and in Combination With Olaparib or Durvalumab in Patients With Solid Tumors

  • NCT04787939 · 89 participants · NA

    Early Feeding After Oral Cavity Reconstruction

  • NCT05480449 · 89 participants · Phase 1

    Autologous HuCART19 T Cells Manufactured Using the CliniMACS Prodigy Platform for Pediatric B-ALL (huCART19 Prodigy)

  • NCT05604131 · 89 participants · Phase 2

    Cardiac MRI-guided Deferiprone Therapy for Acute Myocardial Infarction Patients

Similar registry start date

  • NCT05988463 · started 2027-01-01 · Phase 1

    Dose-Escalation Study of Artesunate Patients With IPF

  • NCT07219706 · started 2026-12-10 · NA

    Dietary Fiber and Time Restricted Eating

  • NCT02831335 · started 2026-12-01

    Technical Development of Multi-Parametric Renocerebral MRI

  • NCT05962346 · started 2026-12 · NA

    Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia

Source: ClinicalTrials.gov NCT01288508, the US trial registry maintained by the National Library of Medicine. NCT01288508 (small enrollment · none site footprint · completed) retrieved and formatted by PlainTrial, see methodology.